Skip to content
Buy This GLP
← Research
Evidence

Fatty Liver and Type 2 Diabetes: A Study of Annual Healthcare Costs

Among matched adults with type 2 diabetes, health care spending was 62% higher after adjustment for those with a recorded fatty liver diagnosis.

Editorial profile: Carla MedinaBuy This GLP Editorial Team4 min read
Mean total healthcare costs, one yearrecorded MASLD$29,734no recorded MASLD$18,320Adjusted difference: $11,411 per person17,412 matched pairs with type 2 diabetes, ages 18–64

What the study measured

Researchers started with 155,172 adults with type 2 diabetes in U.S. IQVIA health-plan claims from January 2016 through June 2025. They matched 17,412 adults with a recorded diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) to 17,412 adults without a recorded diagnosis and compared all-cause direct health care costs over 12 months [1].

The adjusted cost ratio was 1.62 (95% confidence interval 1.58–1.67). The statistical model estimated $11,411 more per person over 12 months (95% CI $10,725–$12,097). Hospital stays accounted for the largest estimated difference, $4,473 per person. The totals include what health plans and patients paid for hospital care, outpatient care, emergency visits and outpatient prescriptions, expressed in 2025 U.S. dollars [1].

How to interpret the spending difference

A comparison group without a recorded diagnosis may include people with undiagnosed MASLD. Guidance on fatty liver screening in type 2 diabetes addresses how clinicians assess the risk of fibrosis. The study records could not distinguish spending by fibrosis stage. Differences in underlying health and health care use can remain after matching, so the study cannot establish how much of the spending gap the disease caused [1].

Estimates of semaglutide’s cost-effectiveness for MASH address a separate question by modeling treatment costs and projected health benefits. The FDA’s accelerated approval for Wegovy injection covers adults with noncirrhotic MASH and moderate-to-advanced fibrosis, consistent with stages F2 to F3 [2]. The claims study included a broader diagnosed MASLD population.

For a prescription, GLP-1 coverage rules depend on the plan, the product and the condition being treated. The study’s combined spending figure cannot tell you what your insurer would cover or how much you would pay at the pharmacy.

Frequently asked

How much higher were healthcare costs for people with fatty liver disease?
Among matched adults aged 18 to 64 with type 2 diabetes, the adjusted annual difference associated with a recorded MASLD diagnosis was $11,411 in 2025 U.S. dollars.
Does taking a GLP-1 lower that cost?
The study cannot answer that. Its GLP-1 subgroup compared people with and without a recorded MASLD diagnosis among those already receiving a GLP-1 drug.
Does the $11,411 estimate describe what a patient pays?
It combines payments from health plans and patients for hospital care, outpatient and emergency services, and prescriptions. It cannot estimate an individual’s out-of-pocket costs.

Sources

  1. [1] Tran TH, et al. (2026). Real-World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study Diabetes, Obesity and Metabolism. PMID 42736030
  2. [2] U.S. Food and Drug Administration (2025). Wegovy accelerated approval for noncirrhotic MASH with moderate-to-advanced liver fibrosis FDA. Source

Where to get it

The cheapest GLP-1

Every seller that publishes a price, ordered lowest first on the standing month-to-month rate, plus the question to ask before you pay any of them.

See the board →

More in Evidence